Darbepoetin trial for people waiting for a liver transplant
Treatments studied
This trial tests if darbepoetin, a medicine that boosts red blood cells, can help people with anemia who are on the liver transplant waiting list. It may improve your strength and prepare you for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are officially listed for a liver transplant
- Your hemoglobin (red blood cell) level is 11.5 g/dL or lower
- If you can become pregnant, you must have a negative pregnancy test and use very effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a pre-surgery exercise and nutrition program (prehabilitation) for people waiting for a liver transplant. It aims to see if getting stronger before surgery can help you recover better after the transplant.
This trial studies how doctors manage bleeding before, during, and after liver transplant surgery. The goal is to improve safety and outcomes for people receiving a new liver.
This trial tests a new oral medication (QLG1218, also called daprodustat) to treat anemia in people with chronic kidney disease who are on hemodialysis. It is comparing the new drug to the usual injected ESA medicines to see if it works as well or better.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
Hear when a new Liver Transplant; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.